Call Us 24/7 - (714) 547-5375
We Accept Most Insurance
ONLINE BENEFITS CHECK
Suboxone is a relatively new medication used by licensed physicians to treat opiate dependence in patients who are addicted to opioid drugs such as oxycodone, heroin and Vicodin. This medication effectively reduces the symptoms of withdrawal from opiates and at the same time decreases the patient's cravings significantly. Suboxone, when prescribed by a qualified physician in the correct dosage can greatly increase the likelihood of a patient staying in treatment and ultimately freeing them of the addiction and cravings.
Campral is a delayed release tablet used for the maintenance of abstinence from alcohol in individuals with alcohol dependence. Campral helps reduce the physical and emotional discomfort many people feel in the weeks and months after they have stopped drinking. Campral has demonstrated success in helping clients maintain long-term sobriety.
Antabuse is used to assist a chronic alcoholic; it acts as a deterrent, creating an unpleasant physical response to drinking alcohol.
Naltrexone (Revia) is a safe, effective oral medication used as part of a comprehensive treatment program as an aid to treat alcohol dependence and opioid addiction. While effective, it must always be remembered that naltrexone is a tool to assist an individual in the process of recovery, and is not a cure in and of itself. Naltrexone is an opiate blocker and prevents all opiate addicts from getting high and reduces cravings for alcohol in the alcoholic.
Vivitrol is the only medication approved for the prevention of relapse to opioid dependence following opioid detoxification. Administered as a once-monthly intramuscular injection by a healthcare professional, Vivitrol is a non-addictive, non-scheduled opioid antagonist that blocks the subjective effects of opioids. In conjunction with a comprehensive management program that includes psychosocial support, Vivitrol is approved for the following:
The FDA approval of Vivitrol for the prevention of relapse to opioid dependence, following opioid detoxification, represents an important new approach as a non-addictive, non-scheduled, opioid antagonist treatment option. This FDA approval was based on data from a 6-month, multicenter, double-blind, placebo-controlled clinical trial.
Since relapse prevention is the focus of treatment at Cornerstone, our professional staff recommend that an independent physician consider these anti-craving medications for our clients as part of a solid foundation for continued, lasting recovery.